Key Findings 1 Tirzepatide reduced major kidney events by 23% vs dulaglutide Events: 6.0% vs 7.6% HR 0.77 (95% CI 0.680.88), p=0.0002 The risk of the primary composite kidney outcomewas 23% lower with tirzepatide than with dulaglutide. 2 Benefits were consistent across CKD risk categories Lowtomoderate risk CKD: HR 0.70 Highrisk CKD: HR 0.79 3 Mechanistic drivers differed by CKD stage Lowtomoderate CKD: Less newonset macroalbuminuria Highrisk CKD: Slower eGFR decline This was primarily driven by a lower rate of new-onset persistent macroalbuminuria and a lower rate of eGFR decline. 4 eGFR decline was significantly slower with tirzepatide Overall difference: +0.29 mL/min/1.73 m per year Highrisk CKD: +0.93 mL/min/1.73 m per year 5 Albuminuria improved more with tirzepatide At 36 months, UACR reductions were greater across CKD categories
Among many provisions, the bill will implement federal community engagement requirements for certain able-bodied adults
Inhibition mechanisms include genomic deletions and altered transcription factor (e.g., PPAR) function
Badania takie jak LEADER, SUSTAIN-6, FLOW, SELECT czy STEP-HFpEF jednoznacznie potwierdzaj ich skuteczno 3, 7, 15, 16
Bei akuten Verletzungen laufen Protokolle typischerweise 48 Wochen kontinuierlich, oder bis die Verletzung abgeheilt ist
